Frail subgroups determine heterogeneous outcomes in older patients with NDMM: long-term follow-up of the HOVON 143 trial
老年新诊断多发性骨髓瘤患者的预后因体弱亚组而异:HOVON 143试验的长期随访
期刊:Blood Advances
影响因子:7.1
doi:10.1182/bloodadvances.2025017394
Smits, Febe; Groen, Kaz; Levin, Mark-David; Stege, Claudia A M; van Kampen, Roel; van der Spek, Ellen; Nijhof, Inger; Bilgin, Yavuz M; Thielen, Noortje; Ludwig, Inge; de Waal, Esther G M; Sandberg, Yorick; Kentos, Alain; Timmers, Gert-Jan; Regelink, Josien C; Westerman, Matthijs; de Heer, Koen; Vekemans, Marie-Christiane; Durdu-Rayman, Nazik; de Graauw, Nicole C H P; Seefat, Maarten R; van de Donk, Niels W C J; Ypma, Paula F; Nasserinejad, Kazem; Zweegman, Sonja